Total Voting Rights & Block Listing Return

RNS Number : 4680Y

Ergomed plc

02 January 2020

 

Date: 2 January 2020

Ergomed plc

TOTAL VOTING RIGHTS AND BLOCK LISTING RETURN

Total Voting Rights

In accordance with the Financial Conduct Authority's Disclosure Guidance and Transparency Rules (DTRs), Ergomed plc (the "Company") announces the following information.

The Company's issued share capital as at 31 December 2019 consisted of 47,286,289 ordinary shares of 1p each, none of which were held in treasury.  Each ordinary share in the capital of the Company carries one voting right. 

The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the DTRs.

Block Listing Six Monthly Return

Name of applicant:		Ergomed plc
Name of scheme:		Ergomed plc Long Term Incentive Plan
Period of return:	From:	1 July 2019	To:	31 December 2019
Balance of unallotted securities under scheme(s) from previous return:		1,202,836
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):		1,500,000
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):		568,877
Equals: Balance under scheme(s) not yet issued/allotted at end of period:		2,133,959
Number and class of securities originally admitted and the date of admission		1,800,000 ordinary shares of 1p each - 2 July 2018
Total number of securities in issue at the end of the period		47,286,289 ordinary shares of 1p each

Name of contact:	Nick Blech - Deputy CFO
Telephone number of contact:	[phone]

 Enquiries:

Ergomed plc	Tel: [phone]
Richard Barfield (Chief Financial Officer)
Numis Securities Limited	Tel: [phone]
Freddie Barnfield/Huw Jeremy (Nominated Adviser)
James Black (Broker)
Consilium Strategic Communications - for UK enquiries	Tel: [phone]
Chris Gardner / Sue Stuart Matthew Neal / Olivia Manser	[e-mail]
MC-Services - for Continental European enquiries	Tel: [phone]
Anne Hennecke

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical trials, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services business includes a full range of high-quality contract research and clinical trial management (CRO) services under the Ergomed brand together with an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, and an internationally recognized specialist expertise in orphan drug development, under the PSR brand. For further information, visit: http://ergomedplc.com.

 

END

 

 

TVRFFFLILSILIII